for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AstraZeneca plc

AZN.L

Latest Trade

8,623.28GBp

Change

-75.72(-0.87%)

Volume

327,991

Today's Range

8,609.00

 - 

8,682.00

52 Week Range

6,499.80

 - 

9,081.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
8,699.00
Open
8,646.00
Volume
327,991
3M AVG Volume
50.53
Today's High
8,682.00
Today's Low
8,609.00
52 Week High
9,081.00
52 Week Low
6,499.80
Shares Out (MIL)
1,549.14
Market Cap (MIL)
134,759.30
Forward P/E
22.76
Dividend (Yield %)
2.32

Next Event

Q3 2021 AstraZeneca PLC Earnings Release

Latest Developments

More

CSL Reaffirms Commitment To Manufacture Astrazeneca Covid Vaccine Into 2022

AstraZeneca's Covid-19 Drug Cocktail Meets Main Goal In Late-Stage Trial

AstraZeneca Files For U.S. Approval Of Drug To Prevent COVID-19

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AstraZeneca plc

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

Industry

Biotechnology & Drugs

Contact Info

1 Francis Crick Avenue

CB2 0AA

United Kingdom

+44.20.73045000

https://www.astrazeneca.com/Home

Executive Leadership

Leif Johansson

Independent Non-Executive Chairman of the Board

Pascal Soriot

Chief Executive Officer, Executive Director

Aradhana Sarin

Chief Financial Officer, Executive Director

Jeffrey A. Pott

Chief Human Resource Officer, General Counsel

Katarina Ageborg

Executive Vice President - Sustainability, Chief Compliance Officer

Key Stats

1.87 mean rating - 30 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

22.1K

2019

24.4K

2020

26.6K

2021(E)

35.0K
EPS (USD)

2018

3.460

2019

3.500

2020

4.020

2021(E)

5.245
Price To Earnings (TTM)
41.67
Price To Sales (TTM)
6.26
Price To Book (MRQ)
10.00
Price To Cash Flow (TTM)
27.27
Total Debt To Equity (MRQ)
175.40
LT Debt To Equity (MRQ)
156.93
Return on Investment (TTM)
8.22
Return on Equity (TTM)
5.64

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up